The Danish company, which expects to hire 691 people over the next five years for the new facility, has 720 employees at its current facility in Johnson County.
The approved drugs are Treiba and Ryzodg 70/30, both treatments for adult diabetes.
The news gave the company’s stock a bounce when the markets opened Monday, leading to a 3 percent increase.
Reports say analysts think Tresiba, a once-a-day, long-acting basal insulin, may be a future blockbuster product for the company.
In a statement, Lars Reblen Sorensen, president and CEO of Novo Nordisk said, “We believe these products offer significant benefits and important treatment options for people with type 1 and type 2 diabetes. The approvals mark an important milestone for Novo Nordisk.”
Novo Nordisk stock (NYSE:NVO) sold at $54/98 midday Monday, up about 9 percent.
